A Phase 1/2 Open-label Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214 Nivolumab and Ipilimumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies

Study Overview

The purpose of this study is to test the safety, tolerability, and effectiveness (how well these drugs work together) of the study drug (NKTR-214) given together with Opdivo?.

Study Description

The purpose of this study is to study the safety, tolerability, and effectiveness of the study drug (NKTR-214) given together with Opdivo.

Additional Information

Participants will be compensated for their participation.


  • IRB Number: 1705311414 (NKTR16-214-02)
  • Research Study Identifier: TX7957
  • Principal Investigator: Roberto Pili, MD

Recruitment Status

Closed
Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.